NDAIM-IVSOLUTION
Approved
Jun 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
ROBAXIN (methocarbamol) by Hikma. Approved for muscle relaxant [epc]. First approved in 1959.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ROBAXIN (methocarbamol) is a centrally-acting muscle relaxant administered via IM or IV injection for acute musculoskeletal pain and spasm. The drug has been on the market since 1959 and is used adjunctively with rest and physical therapy. Its precise mechanism of action remains unclear, though it is believed to work through central nervous system depression.
LOE Approaching
As an aging product approaching loss of exclusivity with moderate competitive pressure (30), brand teams likely focus on portfolio maintenance and cost management rather than aggressive expansion.
Mechanism of Action
Pharmacologic Class:
Muscle Relaxant
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ROBAXIN positions you in a defensive, cost-management environment rather than a growth-stage launch. This role develops expertise in mature product stewardship, payer negotiation, and institutional relationships—valuable for portfolio management careers but limited in innovation exposure.
Brand ManagerProduct Manager
Worked on ROBAXIN at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.